We are bullish on Avid's potential take-private deal by Ampersand and GHO, predicting value creation and optimistic about ...

Fintel reports that on November 7, 2024, RBC Capital downgraded their outlook for Avid Bioservices (NasdaqCM:CDMO) from ...

On Tuesday, Avid Bioservices Inc (CDMO) stock saw a decline, ending the day at $12.23 which represents a decrease of $-0.02 or -0.16% from the prior close of $12.25. The stock opened at $12.25 and ...

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

Avid Bioservices Chief Executive Nick Green said the company’s board considered several options before determining to move ...

Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

According to Avid's CFO, as revenue increases, incremental EBITDA is expected to drop through at an ~50% rate, which is not adequately captured in the transaction price.

The $12.50-per-share takeover has been approved by Avid's board and is scheduled to close in the first quarter of 2025, ...

Avid Bioservices Inc., a Tustin-based biotech company, agreed to go private in an $850-million deal that values the company ...